Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Reports Positive Results from PD-L1 Trial in Solid Tumors

publication date: Sep 23, 2019

CStone Pharma of Suzhou reported early results from a China trial of its PD-L1 candidate at the recent Chinese Society of Clinical Oncology meeting. In a Phase Ib study, CS1001 produced a 38% overall response rate in patients with microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) solid tumors who had been heavily pretreated. CStone said MSI-H/dMMR is common in patients with endometrial cancer, gastric adenocarcinoma, malignant small intestine tumor and colorectal adenocarcinoma. In the trial, most patients had colorectal cancer. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.